Sirion touts Phase III data for eye therapy

Sirion Therapeutics says that a late-stage study of ST-601 for eye inflammation following ocular surgery demonstrated positive results. Difluprednate demonstrated a statistically significant response over a placebo on the eighth day of dosing and maintained superiority through the 15-day treatment period. Based on the preliminary results, the Tampa-based biotech said that it would proceed with an NDA to the FDA.

- here's the release on the data

Related Articles:
Sirion completes Sytera merger. Report
Sirion licenses eye infection gel. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.